sb 203580 has been researched along with geniposide in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (geniposide) | Trials (geniposide) | Recent Studies (post-2010) (geniposide) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 496 | 0 | 371 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J; Fang, L; Fu, J; Ge, D; Li, X; Liu, Z; Ran, J; Ran, Y; Shi, Q; Wang, L; Zhang, H; Zhao, H; Zheng, X; Zhou, Y | 1 |
1 other study(ies) available for sb 203580 and geniposide
| Article | Year |
|---|---|
Geniposide suppresses LPS-induced nitric oxide, PGE2 and inflammatory cytokine by downregulating NF-κB, MAPK and AP-1 signaling pathways in macrophages.
Topics: Animals; Anti-Inflammatory Agents; Butadienes; Cell Line; Cyclooxygenase 2; Dinoprostone; Extracellular Signal-Regulated MAP Kinases; Gardenia; Imidazoles; Inflammation Mediators; Interleukin-6; Iridoids; Lipopolysaccharides; Macrophages, Peritoneal; Male; Mice; Mice, Inbred Strains; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Nitriles; Pyridines; Signal Transduction; Sulfones; Transcription Factor AP-1; Tumor Necrosis Factor-alpha | 2014 |